Free Trial
NASDAQ:RSLS

ReShape Lifesciences Q1 2025 Earnings Report

ReShape Lifesciences logo
$3.16 -0.05 (-1.41%)
Closing price 08/14/2025
Extended Trading
$3.16 0.00 (0.00%)
As of 08/14/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ReShape Lifesciences EPS Results

Actual EPS
$75.92
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ReShape Lifesciences Revenue Results

Actual Revenue
$1.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ReShape Lifesciences Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 20, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

ReShape Lifesciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ReShape Lifesciences Earnings Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
3 Penny Stocks to Watch Now, 8/14/25
See More ReShape Lifesciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ReShape Lifesciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ReShape Lifesciences and other key companies, straight to your email.

About ReShape Lifesciences

ReShape Lifesciences (NASDAQ:RSLS) provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

View ReShape Lifesciences Profile

More Earnings Resources from MarketBeat